J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Executive Summary
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
You may also be interested in...
Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.
J&J CEO Gorsky Handing Over Reins To Vice Chairman Duato
Joaquin Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Alex Gorsky is stepping down due to a family health issue.
J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.